On November 15, 2021, the Beijing Stock Exchange officially opened for trading, and NORTHLAND successfully listed on the BSE, marking another significant step forward on the company's path of pioneering innovation and continuous development, and placing it at a new starting point.

        As a company specializing in the R&D and production of gene therapy drugs, recombinant protein drugs, and ophthalmic medications, NORTHLAND has been listed on the New Third Board since February 2009. Over the past 12 years, it has fully participated in and witnessed the reform and development of the New Third Board. Leveraging the power of the capital market, the company has steadily overcome numerous challenges and achieved continuous, stable, and healthy growth. In November 2020, the company was promoted to the Select Tier of the New Third Board, and in November 2021, it was listed on the Beijing Stock Exchange. All employees are greatly inspired and encouraged, and their original aspirations have become even stronger.

        The Beijing Stock Exchange represents a significant achievement in the continued deepening of reforms on the New Third Board. Positioned to support the innovative development of small and medium-sized enterprises and to become a key platform for serving innovative SMEs, the exchange will provide a more effective platform for companies to secure financing for their future growth. As one of the first listed companies on the Beijing Stock Exchange, the company’s management attaches great importance to this development and is closely monitoring the issuance of various business rules by the exchange. They have promptly organized relevant personnel to study these rules, aiming to meet the operational standards required of listed companies and, at the same time, leverage the Beijing Stock Exchange’s highly efficient financing platform to secure the financial resources necessary for the company’s future development.

        Successfully listing on the Beijing Stock Exchange marks another brand-new starting point on NORTHLAND's development journey. All NORTHLAND employees will remain true to our original aspiration, consistently pursue innovative drug research and development, accelerate clinical trials for key projects, build a high-level biopharmaceutical industrialization base on schedule, and actively prepare for commercialization, striving to bring safe, effective, and high-quality medicines to clinical practice at an early date. At the same time, the company will conscientiously fulfill its obligations as a listed company, continuously improve its governance structure, operate in a standardized manner, ensure proper information disclosure, safeguard the rights and interests of our investors, and endeavor to achieve outstanding business performance, rewarding our shareholders and contributing to society.